Japanese regulatory authority's perspective on biosimilars - authors' reply

Lancet Oncol. 2015 Mar;16(3):e102. doi: 10.1016/S1470-2045(15)70047-1.
No abstract available

Publication types

  • Letter
  • Comment

MeSH terms

  • Antineoplastic Agents / therapeutic use*
  • Biosimilar Pharmaceuticals / standards*
  • Biosimilar Pharmaceuticals / therapeutic use*
  • Drug Approval / legislation & jurisprudence*
  • Humans
  • Neoplasms / drug therapy*

Substances

  • Antineoplastic Agents
  • Biosimilar Pharmaceuticals